RGEN Q3 2024 Earnings — Repligen Corporation Revenue & Financial Results | Market Cap Arena

RGENRepligen Corporation

$7B

Q3 2024 Earnings

Healthcare Medical - Instruments & Supplies

Income Statement

Revenue

$155M+9.7% YoY

Gross Profit

$77M50.0% margin

Operating Income

-$8M-5.1% margin

Net Income

-$654,000-0.4% margin

EPS (Diluted)

$0.32

QoQ Revenue Growth

-2.5%

Cash Flow

Operating Cash Flow

$49M

Free Cash Flow

$42M

Stock-Based Comp.

$23M

Balance Sheet

Total Assets

$2.8B

Total Liabilities

$814M

Stockholders' Equity

$2.0B

Cash & Equivalents

$784M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$155M	$141M	+9.7%
Gross Profit	$77M	$37M	+112.0%
Operating Income	-$8M	$5M	-267.0%
Net Income	-$654,000	$17M	-103.9%

Revenue Segments

Product

$155M100%

Royalty

$37,0000%